Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ACAD
stocks logo

ACAD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
292.66M
+12.73%
0.152
-82.36%
283.10M
+15.88%
0.115
+4.55%
304.72M
+15.18%
0.188
+17.19%
Estimates Revision
The market is revising Upward the revenue expectations for ACADIA Pharmaceuticals Inc. (ACAD) for FY2025, with the revenue forecasts being adjusted by 0.92% over the past three months. During the same period, the stock price has changed by 5.11%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.92%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+53.15%
In Past 3 Month
Stock Price
Go Up
up Image
+5.11%
In Past 3 Month
Wall Street analysts forecast ACAD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACAD is 30.24 USD with a low forecast of 21.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast ACAD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACAD is 30.24 USD with a low forecast of 21.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
5 Hold
0 Sell
Moderate Buy
Current: 26.550
sliders
Low
21.00
Averages
30.24
High
39.00
Current: 26.550
sliders
Low
21.00
Averages
30.24
High
39.00
Mizuho
Neutral
maintain
$24 -> $29
2025-12-02
New
Reason
Mizuho
Price Target
$24 -> $29
2025-12-02
New
maintain
Neutral
Reason
Mizuho raised the firm's price target on Acadia Pharmaceuticals to $29 from $24 and keeps a Neutral rating on the shares. The firm upped the company's sales estimates post the "solid" Q4 report, driven by higher Nuplazid expectations. However, it sees a balanced risk/reward at current share levels.
JPMorgan
Tessa Romero
Overweight
downgrade
$33 -> $31
2025-11-17
Reason
JPMorgan
Tessa Romero
Price Target
$33 -> $31
2025-11-17
downgrade
Overweight
Reason
JPMorgan analyst Tessa Romero lowered the firm's price target on Acadia Pharmaceuticals to $31 from $33 and keeps an Overweight rating on the shares. The firm updated the company's model post earnings.
Citi
initiated
$33
2025-10-21
Reason
Citi
Price Target
$33
2025-10-21
initiated
Reason
Citi initiated coverage of Acadia Pharmaceuticals with a Buy rating and $33 price target. The firm believes Nuplazid and Daybue adoption will continue to increase in the near term. Acadia shares are being over-penalized for Nuplazid sales despite the patent litigation being resolved, the analyst tells investors in a research note.
Deutsche Bank
Buy
downgrade
$35 -> $29
2025-09-25
Reason
Deutsche Bank
Price Target
$35 -> $29
2025-09-25
downgrade
Buy
Reason
Deutsche Bank lowered the firm's price target on Acadia Pharmaceuticals to $29 from $35 and keeps a Buy rating on the shares.
TD Cowen
Buy
maintain
$35 -> $39
2025-09-11
Reason
TD Cowen
Price Target
$35 -> $39
2025-09-11
maintain
Buy
Reason
TD Cowen raised the firm's price target on Acadia Pharmaceuticals to $39 from $35 and keeps a Buy rating on the shares. The firm noted the company is expected to release topline Ph3 PBO-controlled PWS data of ACP-101 (intranasal carbetocin) in early Q4 and after adding the Ph3 PWS program to their pNPV, they raised their target.
UBS
Buy
maintain
$36 -> $39
2025-09-09
Reason
UBS
Price Target
$36 -> $39
2025-09-09
maintain
Buy
Reason
UBS raised the firm's price target on Acadia Pharmaceuticals to $39 from $36 and keeps a Buy rating on the shares. Checks with key opinion leaders increase the firm's confidence in the likelihood of a ACP-101 study win, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for ACADIA Pharmaceuticals Inc (ACAD.O) is 40.09, compared to its 5-year average forward P/E of -7.95. For a more detailed relative valuation and DCF analysis to assess ACADIA Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.95
Current PE
40.09
Overvalued PE
74.17
Undervalued PE
-90.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
68.47
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
377.09
Undervalued EV/EBITDA
-240.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.08
Current PS
0.00
Overvalued PS
8.05
Undervalued PS
2.12
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 713.31% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 713.31% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ACAD News & Events

Events Timeline

(ET)
2025-11-05
16:51:20
Acadia Pharmaceuticals projects FY25 revenue between $1.07B and $1.095B, in line with consensus of $1.07B
select
2025-11-05
16:50:31
Acadia Pharmaceuticals Announces Q3 EPS of 42 Cents, Exceeding Consensus Estimate of 15 Cents
select
2025-09-24 (ET)
2025-09-24
12:32:12
Video: Soleno Therapeutics Shares Surge Following Competitor's Trial Setback
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
11-22NASDAQ.COM
Reasons Behind Dyne Therapeutics Stock Surge This Week

  • Positive Analyst Note: Dyne Therapeutics received a favorable mention in an analyst report from RBC Capital Markets, highlighting its potential in the biotech sector, which has seen a recent rally, leaving some stocks behind.

  • Stock Performance: Following the analyst note, Dyne's stock rose by 11% week-to-date, reflecting investor optimism about the company's prospects in developing therapies for muscle disorders.

  • Market Trends: The RBC report suggests that investors are shifting focus from AI/tech stocks to biotech, indicating a potential for further growth in the sector, particularly for companies like Dyne, Acadia Pharmaceuticals, and others that were overlooked in the recent rally.

  • Investment Considerations: While Dyne Therapeutics shows promise, it was not included in the Motley Fool Stock Advisor's list of the top 10 stocks to buy, which historically have provided significant returns compared to the broader market.

[object Object]
Preview
4.0
11-06Benzinga
In-Depth Insights: 6 Analysts Weigh In on ACADIA Pharmaceuticals Stock

  • Analyst Ratings Overview: In the last three months, 6 analysts have provided ratings for ACADIA Pharmaceuticals, with a mix of bullish and bearish sentiments, resulting in a total of 5 bullish and 1 somewhat bullish ratings in the last 30 days.

  • Price Target Insights: Analysts have set an average 12-month price target of $33.5 for ACADIA Pharmaceuticals, with a high estimate of $39.00 and a low of $28.00, reflecting a slight increase from the previous average of $32.60.

  • Company Background: ACADIA Pharmaceuticals focuses on developing treatments for central nervous system disorders and rare diseases, with key products including NUPLAZID for Parkinson's Disease Psychosis and DAYBUE for Rett syndrome.

  • Financial Performance Indicators: The company shows strong financial health with a net margin of 10.08%, a return on equity of 3.36%, and a debt-to-equity ratio of 0.07, indicating effective cost management and a solid financial structure.

[object Object]
Preview
6.0
11-06Benzinga
Needham Reaffirms Buy Rating on ACADIA Pharmaceuticals and Increases Price Target to $29

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ACADIA Pharmaceuticals Inc (ACAD) stock price today?

The current price of ACAD is 26.55 USD — it has increased 2.59 % in the last trading day.

arrow icon

What is ACADIA Pharmaceuticals Inc (ACAD)'s business?

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

arrow icon

What is the price predicton of ACAD Stock?

Wall Street analysts forecast ACAD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACAD is 30.24 USD with a low forecast of 21.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ACADIA Pharmaceuticals Inc (ACAD)'s revenue for the last quarter?

ACADIA Pharmaceuticals Inc revenue for the last quarter amounts to 278.63M USD, increased 11.27 % YoY.

arrow icon

What is ACADIA Pharmaceuticals Inc (ACAD)'s earnings per share (EPS) for the last quarter?

ACADIA Pharmaceuticals Inc. EPS for the last quarter amounts to 0.42 USD, increased 110.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for ACADIA Pharmaceuticals Inc (ACAD)'s fundamentals?

The market is revising Upward the revenue expectations for ACADIA Pharmaceuticals Inc. (ACAD) for FY2025, with the revenue forecasts being adjusted by 0.92% over the past three months. During the same period, the stock price has changed by 5.11%.
arrow icon

How many employees does ACADIA Pharmaceuticals Inc (ACAD). have?

ACADIA Pharmaceuticals Inc (ACAD) has 653 emplpoyees as of December 05 2025.

arrow icon

What is ACADIA Pharmaceuticals Inc (ACAD) market cap?

Today ACAD has the market capitalization of 4.49B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free